Full-Time

Director/Sr. Director

Regulatory Affairs

Updated on 11/16/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$230k - $290kAnnually

Senior

San Francisco, CA, USA

Hybrid position based in San Francisco, CA.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Word/Pages/Docs
Google Cloud Platform
PowerPoint/Keynote/Slides
Requirements
  • A minimum of a bachelor’s degree is required (life sciences disciplines strongly preferred) with approximately 8 years of experience in the biotechnology or pharmaceutical industries in regulatory affairs or related functions in drug/biologics development/manufacturing (an equivalent combination of education and experience may be considered).
  • Great attention to detail, ability to work on multiple projects with tight deadlines, and ability to work independently.
  • Demonstrated experience leading eCTD formatted submissions, e.g., INDs, NDAs/BLAs, MAAs, annual reports, amendments, and supplements for drugs and/or biologics.
  • Has successfully led responses to health authorities or other critical submissions while maintaining agreed timelines.
  • Ability to communicate regulatory expectations pertaining to the drug development process, FDA/EMA/global guidance and regulations, to cross-functional teams.
  • Excellent oral and written communication and time management skills are essential.
  • Demonstrated ability to work effectively with and/or lead cross-functional team activities, e.g., research, clinical, and CMC team.
  • Ability to develop regulatory plans and strategies while proactively identifying risks.
  • Ability to work on multiple tasks with strong attention to detail to meet company objectives.
  • Knowledge of ICH, GCP, GMP, and other relevant global guidelines.
  • Excellent computer skills, e.g., MS Word, Excel, PowerPoint, and electronic document management software/systems.
Responsibilities
  • Planning, coordination, review, and assembly of regulatory documentation for submission to health authorities (e.g., FDA, EMA, and other global regulatory agencies)
  • Independently or with limited oversight, plan, compile, review, and submit documents for the company, including but not limited to initial INDs/CTAs/NDAs/MAAs and amendments or supplements
  • Provide regulatory direction to project teams in developing and implementing regulatory strategies and plans
  • Develop, maintain, and communicate timelines for regulatory submissions to ensure timely delivery of regulatory documentation
  • Participate in the review of critical documents such as: protocols, ICFs, IBs, CSRs, DSURs, etc. to ensure they are compliant with relevant regulations and guidance (e.g. ICH, FDA, EMA, etc.) prior to submission
  • Coordinate with vendors to appropriately plan and finalize submissions to health authorities in accordance with regulations and guidelines
  • Maintain regulatory databases, including submission and correspondence logs
  • Independently plan daily work to complete time-sensitive assignments
  • Review, write, and present guidelines and SOPs as needed to support high-quality submissions and assure adherence to regulatory requirements
  • Maintain current knowledge of applicable US and global regulations, guidance, and standards for drug development and product registration.

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. The company generates revenue through drug development, licensing agreements, and partnerships, with a diverse pipeline of over 15 drug programs aimed at 20 different genetic diseases. Their culture promotes independent thinking and transparency, enabling quick, data-driven decisions that enhance their drug development process.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

28%

1 year growth

59%

2 year growth

97%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.

Help us improve and share your feedback! Did you find this helpful?